PLAINSBORO, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it is holding its first International Symposium on Tissue Technologies in Lisbon, Portugal, June 16 - 17, 2016.
This event-packed, two-day medical training symposium will bring together over 100 surgeons from Europe, the Middle East and the United States. The sessions will offer an overview of surgical techniques used in various medical fields, such as dermal reconstruction and regeneration, and plastic and reconstructive procedures, which will be presented by a faculty of world-renowned surgeons.
“As a world leader in Tissue Technologies, Integra is very pleased to offer this training and educational symposium, which will bring together some of the world’s leading plastic and reconstructive surgeons with Integra’s regenerative technology solutions,” said Stephane Corp, Integra’s Vice President, Orthopedics & Tissue Technologies, EMEA . “Our vision is to provide soft tissue repair technologies that improve patients’ lives, and we are proud to host an event where attendees can share best practices and techniques. We look forward to working with the surgeons around the globe who share that vision to further research in regenerative products and techniques.”
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.